Cynata and FUJIFILM Sign Development and Commercialisation Partnership Agreement
- Fujifilm takes A$3.97 million strategic equity stake in Cynata
- Parties to collaborate on the further development and commercialisation of Cynata’s lead Cymerus™ therapeutic MSC product CYP-001 for graft-versus-host disease (GvHD)
- Potential future upfront and milestone payments in excess of A$60 million
- Double-digit royalties on CYP-001 product net sales
- Strategic relationship for potential future manufacture of CYP-001 and certain rights to other Cynata technology